125 related articles for article (PubMed ID: 37272319)
1. Probing the mechanism of reduced
Brand CL; Sturis J
Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):225-228. PubMed ID: 37272319
[TBL] [Abstract][Full Text] [Related]
2. Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans.
Porcellati F; Rossetti P; Candeloro P; Lucidi P; Cioli P; Andreoli AM; Ghigo E; Bolli GB; Fanelli CG
J Clin Endocrinol Metab; 2009 Aug; 94(8):3017-24. PubMed ID: 19470629
[TBL] [Abstract][Full Text] [Related]
3. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
[TBL] [Abstract][Full Text] [Related]
4. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.
Home P; Bartley P; Russell-Jones D; Hanaire-Broutin H; Heeg JE; Abrams P; Landin-Olsson M; Hylleberg B; Lang H; Draeger E;
Diabetes Care; 2004 May; 27(5):1081-7. PubMed ID: 15111525
[TBL] [Abstract][Full Text] [Related]
5. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial.
Davies M; Sasaki T; Gross JL; Bantwal G; Ono Y; Nishida T; Tojjar D; Seino H
Diabetes Obes Metab; 2016 Jan; 18(1):96-9. PubMed ID: 26435472
[TBL] [Abstract][Full Text] [Related]
6. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups.
Hompesch M; Troupin B; Heise T; Elbroend B; Endahl L; Haahr H; Heinemann L
Diabetes Obes Metab; 2006 Sep; 8(5):568-73. PubMed ID: 16918592
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes.
Koehler G; Treiber G; Wutte A; Korsatko S; Mader JK; Semlitsch B; Pieber TR
Diabetes Obes Metab; 2014 Jan; 16(1):57-62. PubMed ID: 23841569
[TBL] [Abstract][Full Text] [Related]
8. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
[TBL] [Abstract][Full Text] [Related]
9. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
[TBL] [Abstract][Full Text] [Related]
10. Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study.
Ji J; He Z; Yang Z; Mi Y; Guo N; Zhao H; Gao J; Ma Z; Luo X; Han Z
BMJ Open Diabetes Res Care; 2020 Apr; 8(1):. PubMed ID: 32265255
[TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.
Raskin P; Gylvin T; Weng W; Chaykin L
Diabetes Metab Res Rev; 2009 Sep; 25(6):542-8. PubMed ID: 19565569
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin.
Pieber TR; Draeger E; Kristensen A; Grill V
Diabet Med; 2005 Jul; 22(7):850-7. PubMed ID: 15975098
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
14. Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.
Damci T; Emral R; Svendsen AL; Balkir T; Vora J;
BMC Endocr Disord; 2014 Jul; 14():61. PubMed ID: 25048824
[TBL] [Abstract][Full Text] [Related]
15. Weight change upon once-daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin-naïve individuals with type 2 diabetes: results from the DIET trial.
Niswender K; Piletic M; Andersen H; Conradsen Hiort L; Hollander P
Diabetes Obes Metab; 2014 Feb; 16(2):186-92. PubMed ID: 24112375
[TBL] [Abstract][Full Text] [Related]
16. Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.
Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
Pediatr Diabetes; 2011 Nov; 12(7):632-41. PubMed ID: 21418455
[TBL] [Abstract][Full Text] [Related]
17. Disproportionality analysis of spontaneously reported hypoglycemia events due to insulin use: A comparison between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System.
Jeong D; Kim W; Shin JY
Int J Clin Pharmacol Ther; 2021 Mar; 59(3):224-230. PubMed ID: 33191903
[TBL] [Abstract][Full Text] [Related]
18. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.
Sreenan S; Virkamäki A; Zhang K; Hansen JB;
Int J Clin Pract; 2008 Dec; 62(12):1971-80. PubMed ID: 19166444
[TBL] [Abstract][Full Text] [Related]
19. Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects.
Hallschmid M; Jauch-Chara K; Korn O; Mölle M; Rasch B; Born J; Schultes B; Kern W
Diabetes; 2010 Apr; 59(4):1101-7. PubMed ID: 20068139
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK.
Thalange N; Gundgaard J; Parekh W; Tutkunkardas D
BMJ Open Diabetes Res Care; 2019; 7(1):e000664. PubMed ID: 31543973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
